NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
NeOnc Technologies Holdings (NASDAQ: NTHI) announced its global patent portfolio has reached 176 patents, strengthening its competitive position in oncology and neurology therapeutics. The portfolio includes 126 issued patents (29 U.S. and 97 international) and 50 pending patents (19 U.S. and 31 international).
The company's IP protection covers major pharmaceutical markets including the U.S., EU, China, Japan, Brazil, and Australia. Their lead programs (NEO100, NEO212, NEO214, and NEO400) are protected by extensive patent coverage. NEO100 is covered by eight U.S. patents expiring between 2031-2036, with potential extensions. The company also holds patents for blood-brain barrier permeability compounds with protections until 2039.
NeOnc Technologies Holdings (NASDAQ: NTHI) ha annunciato che il suo portafoglio globale di brevetti ha raggiunto 176 brevetti, rafforzando la sua posizione competitiva nei trattamenti oncologici e neurologici. Il portafoglio include 126 brevetti concessi (29 negli Stati Uniti e 97 a livello internazionale) e 50 brevetti in attesa (19 negli Stati Uniti e 31 internazionali).
La protezione della proprietà intellettuale dell’azienda copre i principali mercati farmaceutici, inclusi Stati Uniti, UE, Cina, Giappone, Brasile e Australia. I loro programmi principali (NEO100, NEO212, NEO214 e NEO400) sono tutelati da un’ampia copertura brevettuale. NEO100 è coperto da otto brevetti statunitensi con scadenza tra il 2031 e il 2036, con possibilità di estensioni. L’azienda detiene inoltre brevetti per composti che attraversano la barriera emato-encefalica, protetti fino al 2039.
NeOnc Technologies Holdings (NASDAQ: NTHI) anunció que su cartera global de patentes ha alcanzado 176 patentes, fortaleciendo su posición competitiva en terapias oncológicas y neurológicas. La cartera incluye 126 patentes concedidas (29 en EE.UU. y 97 internacionales) y 50 patentes en trámite (19 en EE.UU. y 31 internacionales).
La protección de propiedad intelectual de la compañía cubre los principales mercados farmacéuticos, incluyendo EE.UU., UE, China, Japón, Brasil y Australia. Sus programas principales (NEO100, NEO212, NEO214 y NEO400) cuentan con una amplia cobertura de patentes. NEO100 está protegido por ocho patentes estadounidenses que expiran entre 2031 y 2036, con posibles extensiones. La empresa también posee patentes para compuestos que atraviesan la barrera hematoencefálica, con protección hasta 2039.
NeOnc Technologies Holdings (NASDAQ: NTHI)는 전 세계 특허 포트폴리오가 176건에 도달했다고 발표하며, 종양학 및 신경학 치료 분야에서 경쟁력을 강화했습니다. 포트폴리오에는 126건의 등록 특허(미국 29건, 국제 97건)와 50건의 출원 중인 특허(미국 19건, 국제 31건)이 포함되어 있습니다.
회사의 지적 재산권 보호는 미국, EU, 중국, 일본, 브라질, 호주 등 주요 제약 시장을 포함합니다. 주요 프로그램(NEO100, NEO212, NEO214, NEO400)은 광범위한 특허 보호를 받고 있습니다. NEO100은 2031년부터 2036년 사이에 만료되는 8건의 미국 특허로 보호되며, 연장 가능성이 있습니다. 또한 혈액뇌장벽 투과 화합물에 대한 특허를 보유하고 있으며, 2039년까지 보호됩니다.
NeOnc Technologies Holdings (NASDAQ : NTHI) a annoncé que son portefeuille mondial de brevets a atteint 176 brevets, renforçant ainsi sa position concurrentielle dans les thérapies en oncologie et neurologie. Le portefeuille comprend 126 brevets délivrés (29 aux États-Unis et 97 à l’international) et 50 brevets en cours (19 aux États-Unis et 31 internationaux).
La protection de la propriété intellectuelle de la société couvre les principaux marchés pharmaceutiques, notamment les États-Unis, l’UE, la Chine, le Japon, le Brésil et l’Australie. Leurs programmes phares (NEO100, NEO212, NEO214 et NEO400) bénéficient d’une large couverture de brevets. NEO100 est protégé par huit brevets américains expirant entre 2031 et 2036, avec des extensions possibles. L’entreprise détient également des brevets pour des composés franchissant la barrière hémato-encéphalique, protégés jusqu’en 2039.
NeOnc Technologies Holdings (NASDAQ: NTHI) gab bekannt, dass sein globales Patentportfolio 176 Patente erreicht hat und damit seine Wettbewerbsposition in der Onkologie- und Neurologie-Therapie stärkt. Das Portfolio umfasst 126 erteilte Patente (29 in den USA und 97 international) sowie 50 anhängige Patente (19 in den USA und 31 international).
Der Schutz des geistigen Eigentums des Unternehmens erstreckt sich auf wichtige Pharmamärkte wie die USA, die EU, China, Japan, Brasilien und Australien. Ihre führenden Programme (NEO100, NEO212, NEO214 und NEO400) sind durch umfangreichen Patentschutz abgesichert. NEO100 ist durch acht US-Patente geschützt, die zwischen 2031 und 2036 ablaufen, mit möglichen Verlängerungen. Das Unternehmen hält außerdem Patente für Blut-Hirn-Schranken-durchlässige Verbindungen, die bis 2039 geschützt sind.
- Strong patent protection with 176 total patents across major global markets
- Lead product NEO100 protected until 2036 with potential extensions
- Blood-brain barrier technology patents extend to 2039
- NEO212 and NEO214 eligible for Orange Book listing and data exclusivity
- Some key patents begin expiring as early as 2031
-- 176 Patents Issued and Outstanding Reinforces NeOnc’s Competitive Position --
CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position.
The Company’s IP portfolio, covering its core pipeline, currently comprises 126 issued patents - 29 in the United States and 97 internationally; and 50 pending patents - 19 in the United States and 31 internationally.
NeOnc’s expanding IP portfolio reflects its innovation engine as well as its commitment to protecting and maximizing the commercial potential of its therapeutic candidates, globally. The Company’s IP protections span all major pharmaceutical markets, including the U.S., European Union, China, Japan, Brazil, and Australia, as the Company advances its portfolio of next-generation therapeutics toward regulatory approval.
“Intellectual property is a cornerstone of our strategy, and the strength of our global patent portfolio reflects the depth of our innovation and the breadth of our ambition,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “This portfolio enhances our ability to protect our breakthroughs in oncology and neurology, including our intranasal drug delivery platform, and safeguards our proprietary capability to bio-conjugate existing standard-of-care treatments like TMZ. Together, these protections ensure a strong foundation for long-term value creation for shareholders and life-changing solutions for patients.”
NeOnc’s lead programs — including NEO100, NEO212, NEO214, and NEO400 — are protected by extensive patent coverage, notably:
- NEO100, ultrapure perillyl alcohol, which is covered by eight U.S. patents expiring between 2031 and 2036, with potential extensions via the FDA’s patent term extension program and additional exclusivity through NEO100’s Orphan Drug Designation.
- NEO212 and NEO214, structurally unique perillyl alcohol conjugates, which benefit from Orange Book eligibility and new chemical entity data exclusivity provisions post-approval.
- NEO400, a topical anticancer agent, that recently has secured broad patent coverage in Europe, with similar filings underway globally.
- Additionally, the Company holds key patents for the use of its compounds in permeabilizing the blood-brain barrier, with protections extending into 2039.
“Our mission is to bring paradigm-shifting therapies to patients with some of the most challenging conditions, and our growing patent estate gives us the platform to do just that,” said Dr. Thomas Chen, CEO of NeOnc Technologies. “We will continue to invest aggressively in IP as we advance toward clinical and regulatory milestones across our pipeline.”
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit neonc.com.
Important Cautions Regarding Forward Looking Statements
All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate,” or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.
“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.
Company Contact:
Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
info@neonc.com
Investor Relations:
Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
rpondel@pondel.com/lberman@pondel.com
FAQ
How many patents does NeOnc Technologies (NTHI) currently hold globally?
When do NeOnc Technologies' (NTHI) NEO100 patents expire?
What are the key markets covered by NeOnc Technologies' (NTHI) patent portfolio?
How long does NeOnc Technologies' (NTHI) blood-brain barrier patent protection extend?
